AU2020402031A1 - Biomolecule for treatment of corneal pathologies - Google Patents

Biomolecule for treatment of corneal pathologies Download PDF

Info

Publication number
AU2020402031A1
AU2020402031A1 AU2020402031A AU2020402031A AU2020402031A1 AU 2020402031 A1 AU2020402031 A1 AU 2020402031A1 AU 2020402031 A AU2020402031 A AU 2020402031A AU 2020402031 A AU2020402031 A AU 2020402031A AU 2020402031 A1 AU2020402031 A1 AU 2020402031A1
Authority
AU
Australia
Prior art keywords
comeal
dha
nerve
cornea
rvd6si
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020402031A
Other languages
English (en)
Inventor
Haydee BAZAN
Nicolas G. Bazan
Bokkyoo Jun
Nicos A. Petasis
Thang L. PHAM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California
Louisiana State University
Original Assignee
University of Southern California
Louisiana State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California, Louisiana State University filed Critical University of Southern California
Publication of AU2020402031A1 publication Critical patent/AU2020402031A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2020402031A 2019-12-09 2020-12-09 Biomolecule for treatment of corneal pathologies Pending AU2020402031A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962945580P 2019-12-09 2019-12-09
US62/945,580 2019-12-09
PCT/US2020/064042 WO2021119146A1 (en) 2019-12-09 2020-12-09 Biomolecule for treatment of corneal pathologies

Publications (1)

Publication Number Publication Date
AU2020402031A1 true AU2020402031A1 (en) 2022-06-30

Family

ID=76330542

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020402031A Pending AU2020402031A1 (en) 2019-12-09 2020-12-09 Biomolecule for treatment of corneal pathologies

Country Status (8)

Country Link
US (2) US20230019568A1 (enExample)
EP (1) EP4072578A4 (enExample)
JP (1) JP2023504205A (enExample)
CN (1) CN115038434A (enExample)
AU (1) AU2020402031A1 (enExample)
BR (1) BR112022011276A2 (enExample)
CA (1) CA3161233A1 (enExample)
WO (1) WO2021119146A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4311554A1 (en) * 2022-07-29 2024-01-31 Dompé farmaceutici S.p.a. Combination for use in ophthalmology

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100303887A1 (en) * 2007-07-30 2010-12-02 Bazan Nicolas G DHA and PEDF, a Therapeutic Composition for Nerve and Retinal Pigment Epithelial Cells
CN103191129A (zh) * 2007-10-12 2013-07-10 C.T.辨析有限公司 治疗眼睛病症的脂氧化物类化合物
TW201039815A (en) * 2009-04-13 2010-11-16 Resolvyx Pharmaceuticals Inc Compositions and methods for the treatment of inflammation
US10154977B2 (en) * 2011-03-25 2018-12-18 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
AU2013259503B2 (en) * 2012-05-10 2017-03-16 Solutex Na Llc Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
PL2887923T3 (pl) * 2012-08-24 2023-08-14 Sun Pharmaceutical Industries Limited Preparat okulistyczny polioksylipidu lub polioksylowego kwasu tłuszczowego i leczenie chorób oczu
US20220226270A1 (en) * 2019-04-04 2022-07-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use
WO2022056311A1 (en) * 2020-09-10 2022-03-17 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use

Also Published As

Publication number Publication date
US20230019568A1 (en) 2023-01-19
CA3161233A1 (en) 2021-06-17
BR112022011276A2 (pt) 2022-09-06
EP4072578A1 (en) 2022-10-19
WO2021119146A1 (en) 2021-06-17
EP4072578A4 (en) 2024-01-10
JP2023504205A (ja) 2023-02-01
CN115038434A (zh) 2022-09-09
US20260224521A1 (en) 2026-08-06

Similar Documents

Publication Publication Date Title
Zernii et al. Mitochondria‐Targeted Antioxidant SkQ1 Prevents Anesthesia‐Induced Dry Eye Syndrome
Toops et al. Cholesterol-mediated activation of acid sphingomyelinase disrupts autophagy in the retinal pigment epithelium
Wilke et al. Complement regulation in the eye: implications for age-related macular degeneration
Al-Saedi et al. Dry eye disease: present challenges in the management and future trends
Lim et al. Lipid-based therapy for ocular surface inflammation and disease
Pham et al. Novel RvD6 stereoisomer induces corneal nerve regeneration and wound healing post-injury by modulating trigeminal transcriptomic signature
Nguyen et al. Dry eye disease: A review of anti-inflammatory therapies
Zhang et al. Effects of pranoprofen on aqueous humor monocyte chemoattractant protein-1 level and pain relief during second-eye cataract surgery
Ji et al. Inhibition of ceramide de novo synthesis ameliorates meibomian gland dysfunction induced by SCD1 deficiency
US20200163921A1 (en) METHODS OF TREATING CHRONIC DRY EYE DISEASE USING C16:1n7-PALMITOLEATE AND DERIVATIVES THEREOF
Sukhorukov et al. Molecular mechanisms of interactions between mitochondria and the endoplasmic reticulum: a new look at how important cell functions are supported
CN105997973A (zh) 用于角膜上皮病变和/或结膜上皮病变的治疗剂或预防剂
Kim et al. Oral hyaluronic acid supplementation for the treatment of dry eye disease: a pilot study
CN112040966A (zh) 治疗干眼症
Chen et al. Biochanin A: Disrupting the inflammatory vicious cycle for dry eye disease
Kivinen The role of autophagy in age-related macular degeneration
US20230019568A1 (en) Biomolecule for treatment of corneal pathologies
WO2011097577A2 (en) Compositions and methods for treating or preventing retinal degeneration
Wang et al. Melatonin Ameliorates Circadian Disruption‐Associated Dry Eye via Modulation of BMAL1‐REV‐ERBα‐IL‐17 Axis and Ocular Surface Microbiota Homeostasis
CA2723139A1 (en) Dha and pedf, a therapeutic composition for nerve and retinal pigment epithelial cells
Hong et al. Mechanism of dry eye syndrome improvement by Tetraselmis chuii: Anti-inflammatory effects and ocular mucous membrane restoration
Temnik et al. Intravenous 64Zn-aspartate mitigates neuroinflammation and motor dysfunction in an LPS-induced Parkinson’s disease rat model
HK40080196A (en) Biomolecule for treatment of corneal pathologies
Fahmy et al. Treating ocular surface disease: new agents in development
Bazan et al. A new R, R-RvD6 isomer with protective actions following corneal nerve injury